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Background: Studies have indicated a relationship between hypertension and cognitive 
function. The possible effect of antihypertensive therapy on cognitive disorders is therefore a 
matter of interest.
Materials and methods: The Observational Study on Cognitive function And SBP Reduction 
(OSCAR) was an open-label, multinational trial designed to evaluate the impact of eprosartan-
based antihypertensive therapy on cognitive function in patients with essential hypertension. 
Eprosartan 600 mg/day for 6 months (with provision for additional medication as needed) was 
initiated in hypertensive subjects aged $50 years. A total of 853 patients in an intention-to-treat 
cohort from seven countries of the Middle East was identified for subgroup analysis.
Results: Arterial blood pressure was reduced significantly (P , 0.001) during the study: 
At the end of 6 months of eprosartan-based therapy, the mean (±SD) reduction from baseline 
was 32.1 ± 14.3/14.6.3 ± 8.6 mmHg (P , 0.001). Mean pulse pressure was reduced by 
18.3 ± 13.1 mmHg (P , 0.0001 vs baseline). Blood pressure was normalized (systolic ,140 mmHg 
and diastolic ,90 mmHg) in 68.2% of patients. The overall mean Mini-Mental State Examina-
tion (MMSE) score after 6 months of eprosartan-based therapy was one-point higher than at 
baseline (P , 0.001). MMSE score on completion of 6 months’ follow-up was either unchanged 
or increased from baseline in 793 (93%) individuals and decreased in 60 (7%). Factors associ-
ated with stability of or improvement in cognitive function included MMSE score at baseline, 
diastolic blood pressure (DBP) at baseline, and treatment-induced change in DBP.
Conclusion: Results from the Middle East subgroup of OSCAR are supportive of the hypothesis 
that antihypertensive therapy based on angiotensin-receptor blocker therapy with eprosartan 
may be associated with preservation or improvement of cognitive function.
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Introduction
The Observational Study on Cognitive function And SBP Reduction (OSCAR) 
  provided opportunities to investigate possible effects of eprosartan-based hypertension 
therapy on trends in cognitive performance in a very large community-dwelling popu-
lation of patients with arterial hypertension managed in primary care.
The rationale and methodology of OSCAR have been described elsewhere1 and the 
principal findings from the overall study population have been reported.2 An original 
feature of this international cohort study is the recruitment of patients from countries not 
usually widely represented in such clinical research programs. This lack of participation 
contributes to the shortage of epidemiological data from these regions of the world. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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We now report the findings of a subgroup analysis of data from 
participants recruited in countries of the Middle East.
Materials and methods
OSCAR was conducted in 28 countries.1,2 The present 
subgroup analysis deals with data from patients recruited 
in Bahrain, Jordan, Kuwait, Lebanon, Qatar, Saudi Arabia, 
and the United Arab Emirates.
Male or female patients aged $50 years with newly 
  diagnosed hypertension (systolic blood pressure [SBP] $ 
140 mmHg) could participate in OSCAR if they were   eligible 
for treatment with eprosartan 600 mg/day once daily. 
  Additional antihypertensive medication could be introduced 
after 1 month if the investigator considered the change in SBP 
to be insufficient. Hydrochlorothiazide 12.5 mg/day given in 
a fixed-dose combination with eprosartan was preferred as 
the first add-in medication but investigators were allowed to 
choose whatever drug(s) they considered appropriate.
Blood pressure and safety data were collected at baseline, 
1–3 months, and at 6 months. The Mini-Mental State 
Examination (MMSE)3 was used to assess cognitive function 
at baseline and at the end of the study. Validated local-
language editions of the MMSE were issued to investigators, 
along with instructions for and information about correct 
implementation of the test.
statistical considerations
Analyses were based primarily on the modified intention-
  to-treat (ITT) population, defined as all patients who received 
at least one dose of study treatment and who provided eligible 
relevant values at baseline and from at least one post baseline 
visit. The changes in MMSE score and arterial blood pressure 
between the baseline and post baseline visits were examined 
by a one sample t-test.
Nominal qualitative variables were analyzed using the 
Chi-square test. Ordinal qualitative variables were   compared 
using the Wilcoxon test or the Mantel–Haenzel test, and quan-
titative variables were analyzed using analysis of variance 
(ANOVA). MMSE scores and blood pressure variables 
were compared between visits using covariance analysis, 
with baseline value as the covariate. Results are   presented 
as means with standard deviations, with the exception of 
results derived from ANOVA, where the standard error of 
the mean was calculated.
A logistic regression analysis was used to assess the 
determinants of cognitive decline.
All statistical tests were performed using SAS software 
(v 9.1.3; SAS Institute, Cary, NC).
Results
Patients and baseline characteristics
A total of 42,412 patients was enrolled in OSCAR. Of these, 
1317 were recruited from the seven countries of the Middle 
East participating in the study. A total of 853 patients was 
included in the Middle East ITT cohort (MEC), representing 
64.8% of the total Middle East OSCAR population and 3.3% 
of the total ITT cohort (N = 25745). The derivation of that 
cohort is illustrated in Figure 1. The mean duration of therapy 
in the MEC was 178.5 ± 52.1 days.
Baseline characteristics of the MEC are summarized in 
Table 1. Compared with the residuum of the ITT population 
(RITT), the MEC was younger by an average of 4 years 
and had higher mean body mass index and mean arterial 
blood pressure (∆4 mmHg for both SBP and diastolic 
Included Middle East patients
(N = 1317)
Middle East ITT cohort
(N = 853)
- Received no dose of eprosartan at 4 weeks (n = 192)
- No MMSE at baseline or at end of study (n = 53)
- MMSE score ≤11 at baseline (n = 16)
- MMSE score ≤11 at end of study (n = 5) 
- No blood pressure measurements at baseline (n = 36)
- No blood pressure measurements at least one thereafter (n = 162) 
Excluded patients = patients not meeting the following criteria (n = 464*)
Figure 1 cOnsORT summary for the Mec iTT cohort.
*Patients can meet multiple exclusion criteria.
Abbreviations: iTT, intention-to-treat; MMse, Mini-Mental state examination; Mec, Middle east iTT cohort.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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blood pressure [DBP]). Diabetes (39% vs 23%) and left 
ventricular hypertrophy (25% vs 19%) were proportionately 
more prevalent in the MEC, where as hypercholesterolemia 
(56% vs 63%), coronary artery disease (11% vs 15%), 
and arteriosclerosis (17% vs 21%) were all less frequently 
recorded in MEC (P , 0.001 for all comparisons).
Initial MMSE score was significantly lower in the MEC 
than in the RITT (P , 0.001; Table 1); baseline MMSE 
score ,25 was recorded in a higher proportion of MEC 
patients (n = 243 [28.5% vs 19%]) indicating moderate cog-
nitive impairment. (No statistical test of this difference was 
performed.) A further 257 patients (30.1%) in the MEC had 
MMSE score 25–28, indicating mild cognitive   impairment 
(vs 36.4% of RITT). Average baseline MMSE score was 
higher in men than in women in the MEC (26.9 ± 3.9 vs 
24.9 ± 4.6; P , 0.001). Trends were identified for a higher 
MMSE score with higher level of formal education and 
a lower MMSE score with advancing age (P , 0.001 for 
both).
At baseline, 607 patients were recorded as being pre-
scribed no or one antihypertensive drug, 150 were being 
prescribed two drugs, and the remaining patients were receiv-
ing three or more antihypertensive drugs. After entry into 
the study, 459 patients (53.8%) were assigned to eprosartan 
monotherapy, 237 (27.8%) to treatment with two drugs, and 
157 (18.4%) to three or more drugs. Supplementary medica-
tions were mostly beta blockers, calcium channel blockers 
or nonhydrochlorothiazide diuretics. At baseline, MEC 
patients on monotherapy had a higher mean MMSE (26.4) 
than those who were on multiple combination therapy (25.3) 
(P = 0.017). At the conclusion of the study, 459 patients in the 
MEC were using eprosartan only, 237 were taking eprosartan 
plus one other drug and 157 were using at least three drugs. 
This distribution was similar to that in the RITT.
Blood pressure response
Arterial  blood  pressure  (SBP/DBP)  decreased  to 
132.7 ± 10.5/82 ± 6.3 mmHg over the course of the study 
(P , 0.001 vs baseline for both SBP and DBP). Mean blood 
pressure reduction was 32.9 ± 14.3/14.6 ± 8.6 mmHg 
(P , 0.001). These responses were significantly larger than 
those in the RITT (−25.6 ± 14.0 mmHg systolic, −12.2 ± 
9.1 mmHg diastolic; P , 0.001 for MC vs RITT). Most 
(≈79%) of the net blood pressure reductions were recorded 
between baseline and the first in-study visit (ie, during the 
first 12 weeks of the study).
Mean pulse pressure was reduced by 18.3 ± 13.1 mmHg, 
a significant reduction from baseline and larger than that 
in the RITT (13.6 ± 12.9 mmHg; P , 0.001 for both 
comparisons). Normalization of blood pressure, defined as 
SBP , 140 mmHg and DBP , 90 mmHg, was recorded in 
582 MEC patients (68.2%); this result compared favorably 
with the normalization rate in the RITT (59.5%; P = 0.001). 
A response to therapy, defined as SBP , 140 mmHg and/or 
reduction in SBP $ 15 mmHg or DBP , 90 mmHg and/or 
reduction in DBP $ 10 mmHg was recorded in 763 patients 
(89.4%; vs RITT 91.6%; P = 0.026).
evolution of MMse score
The overall mean MMSE score in the MEC after 6 months of 
eprosartan-based therapy was 27.2 ± 3.6, a 1-point increase 
Table 1 Baseline characteristics of the Middle east iTT population 
(n = 853)
MEC  
(n = 853)
RITT  
(n = 24892)
Bahrain 28 (2.1) –
Jordan 92 (7.0) –
Kuwait 210 (15.9) –
Lebanon 169 (12.8) –
Qatar 108 (8.2) –
saudi Arabia 496 (37.7) –
United Arab emirates 214 (16.3) –
Age (years); mean ± sDa 57.9 ± 7.0 64.4 ± 9.5
no. of males/femalesa 529/323  
(62/38)
12481/12338   
(50/50)
BMi (kg/m2); mean ± sDa 29.5 ± 4.2 27.6 ± 4.1
sBP (mmHg); mean ± sDa 165.6 ± 14.5 161.8 ± 12.9
DBP (mmHg); mean ± sDa 96.6 ± 9.0 92.9 ± 8.8
Pulse pressure (mmHg); mean ± sDb 69.0 ± 14.1 68.8 ± 12.8
Type of hypertensiona
isolated systolic hypertension 132 (15.5) 6528 (26.6)
systo-diastolic hypertension 717 (84.4) 17999 (73.1)
Tobacco use
smokers 224 (27.6) 4,839 (20.7)
ex-smokers 143 (17.6) 6,334 (27.1)
nonsmokers 444 (54.8) 12,170 
(52.2)
Hypercholesterolemiaa 467 15,461
Diabetesa 325 5,679
Family history of cardiovascular diseasea 300 11,507
coronary artery diseasea 95 3,587
Left ventricular hypertrophya 203 4,556
Angina pectorisa 71 3,064
MMse score;* mean ± sDa 26.1 ± 4.3* 27.1 ± 3.3
MMse , 25 243 (28.5) 4645 (18.7)
MMse 25–28 257 (30.1) 9105 (36.6)
MMse . 28 353 (41.4) 11142 (44.8)
Notes: Unless stated otherwise, values shown represent numbers of patients, with 
percentages in parentheses. Data from the residuum of the intention-to-treat (iTT) 
population (RiTT) are included for comparison. *Maximum possible score = 30; 
mean scores for men and women were 26.9 ± 3.9 and 24.9 ± 4.6, respectively   
(P , 0.001 by AnOVA). aP , 0.001; bP = 0.723; cP = 0.513.
Abbreviations: BMi, body mass index; sBP, systolic blood pressure; DBP, diastolic 
blood pressure; MMse, Mini-Mental state examination.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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from the baseline value (P , 0.001). In the RITT cohort 
(n = 24,892) the corresponding MMSE values were 27.1 ± 3.3 
and 27.9 ± 2.8: this 0.8 increase from the baseline value was 
also significant (P , 0.001). MMSE score post baseline was 
either unchanged (n = 392) or increased (n = 401) from baseline 
(N = 793; 93.0%) and decreased in 60 individuals (7.0%).
No statistically significant influences on the evolution of 
MMSE score were demonstrated for sex, age, level of formal 
education, or residence (urban vs rural). Test performance within 
each category of baseline MMSE score (,25, 25–28, 29–30) 
did not vary substantially between baseline and the end of the 
study. The factors most strongly associated with stability of or 
improvement in cognitive function were MMSE score at base-
line, DBP at baseline and in-study change in DBP (Table 2).
safety and tolerability
A total of seven treatment-emergent adverse drug reactions 
(ADRs) was recorded in the Middle East safety population 
(n = 1317), of which four were considered to be possi-
bly (n = 2), probably (n = 1), or highly probably (n = 1) related 
to study medication. One ADR led to treatment termination 
and two to study discontinuation. None of the recorded ADRs 
was classified as severe or serious. Nervous system disorders 
(three events in three patients) were the most frequently 
recorded form of ADR. No deaths occurred in the MEC.
Discussion
This analysis of the MEC is the largest source of prospec-
tively gathered data about cognitive status in patients in the 
Middle East undergoing eprosartan-based antihypertensive 
therapy. In this population, as in the larger OSCAR ITT 
cohort, eprosartan-based therapy for a period of 6 months 
was associated with significant improvement in MMSE score. 
These data are prima facie consistent with earlier reports of 
improved cognitive function associated with a reduction in 
arterial blood pressure.4 Our study is the first of its type to 
report the influence of blood pressure on cognitive function 
for the countries of the Middle East.
Correlations between the evolution of MMSE score and 
arterial blood pressure responses in the MEC were more 
marked for DBP than SBP (though even for DBP the asso-
ciation was not strong (Table 2)). This primacy of DBP is 
somewhat at variance with the overall results of OSCAR but in 
keeping with the work of Elias et al,5 who have proposed that 
diminished cognitive performance is an essential intermediary 
between high blood pressure and physical disability, and who 
have identified, via path analysis, numerous aspects of cogni-
tive function linking higher blood pressure with loss of physi-
cal ability. It should be noted also that the reduction in pulse 
pressure with eprosartan in the MEC was large (∆18.3 mmHg; 
P , 0.001 vs RITT). Effects of eprosartan on aortic pulse wave 
velocity have been documented and related to impairment 
of cognition.6–9 Pulse pressure may act as a crude proxy for 
such effects, and may reflect a reduction in arterial stiffness in 
response to angiotensin-receptor blocker (ARB) therapy.10
Dementia is one of the principal neurological disorders 
leading to loss of autonomic function in the elderly. Although 
demographic trends and social practices in the Arab world mean 
that the impact of dementia is likely to be less marked in the 
short and medium term than in other regions of the world, mea-
sures to limit the risk of developing dementia are self-evidently 
desirable as a contribution to the health of older persons.11 
Observational data in older Arab men suggest a correlation 
between higher blood pressure and cognitive impairment,12 
whereas other reports have documented an extensive prevalence 
of classic cardiovascular risk factors and a rising prevalence of 
metabolic syndrome in Arab populations.13–18 The possibility 
of preserving cognitive function coincidentally in conjunction 
with efforts to reduce hypertension-related cardiovascular risk 
is therefore an attractive idea and has contributed to interest in 
the possibility that antihypertensive therapy, particularly ARB 
therapy targeted at the brain renin–angiotensin system (B-RAS), 
may have beneficial effects on cognition (see Fournier et al9 
for recent discussions of some possible mechanisms of benefit 
beyond blood pressure reduction, and Takeda et al19 for some 
recent perspectives on the concept of the B-RAS). Our findings 
are compatible with that possibility. It should be noted, how-
ever, that although statistically significant to quite a high degree 
(P , 0.001), our blood pressure and MMSE data come from a 
relatively small subgroup and their clinical relevance has to be 
considered in that context. In addition it has to be acknowledged 
that the study did not include a control group.
Experience in the MEC confirms the effectiveness and 
tolerability of eprosartan as a blood pressure-lowering agent, 
whether used alone or in combination. The clinical benefits 
likely to flow from reductions in arterial blood pressure 
have been amply demonstrated. Evidence from several 
ARB studies of reductions in stroke risk and   new-onset 
Table  2  Factors  associated  with  stability  of  or  increase  in   
MMse score
Factor OR (95% CI)
Baseline MMse score 0.93 (0.87–1.0)
Baseline DBP 0.95 (0.91–1.0)
∆DBP 0.96 (0.91–1.0)
Abbreviations:  CI,  confidence  interval;  DBP,  diastolic  blood  pressure;  MMSE, 
Mini-Mental state examination; OR, odds ratio.Vascular Health and Risk Management
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diabetes may be especially relevant, given that the MEC 
was a population characterized by high prevalences of left 
  ventricular hypertrophy and the elements of metabolic 
syndrome, and given concerns about improving stroke aware-
ness and hypertension control in the Middle East.20
The tolerability of eprosartan in the MEC subset of 
OSCAR was very good, as in the study overall. The recorded 
ADR incidence of ≈1.5% (of which none were classified 
as either serious or severe) is compatible with the overall 
findings of OSCAR, experience in randomized trials of 
eprosartan, and the characterization of ‘placebo-like’ 
tolerability21 for this drug. No deaths occurred in the MEC 
and those that were recorded elsewhere during the study were 
not associated with the use of eprosartan.
In conclusion, use of eprosartan as sole or primary 
hypertension medication was associated with an increase in 
the mean MMSE score in this subpopulation of the OSCAR 
study. These observations support the proposition that use 
of eprosartan to treat hypertension may delay or prevent 
cognitive decline in people with high blood pressure.
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